Blog
RSS FeedPosted by Michael Wonder on 19 Apr 2022
Lenvatinib and pembrolizumab in endometrial cancer: patients live significantly longer
19 April 2022 - There is an indication of a considerable added benefit compared to doxorubicin or paclitaxel. Compared to ...
Posted by Michael Wonder on 01 Mar 2022
Triple negative breast cancer: survival benefit with sacituzumab govitecan
1 March 2022 - Those affected survive a median of twelve months compared to seven in the control group. Overall, ...
Posted by Michael Wonder on 15 Feb 2022
Pembrolizumab in combination with chemotherapy: significant additional benefit in advanced squamous cell carcinoma of the oesophagus
15 February 2022 - Those affected survived a median of 14 months compared to nine in the control group. However, an ...
Posted by Michael Wonder on 02 Feb 2022
New EU regulation on health technology assessment of cancer medicines
1 February 2022 - On Dec 15, 2021, the EU adopted a new regulation to harmonise health technology assessment of new ...
Posted by Michael Wonder on 20 Jan 2022
Immunotherapy with blinatumomab improves the chances of survival in very rare childhood blood cancer
20 January 2022 - The Federal Joint Committee (G-BA) today classified the additional benefit of the active ingredient blinatumomab as significant ...
Posted by Michael Wonder on 04 Jan 2022
Daratumumab in multiple myeloma: reassessment results in hint of considerable added benefit
3 January 2022 - Janssen applied for a new early benefit assessment due to new scientific findings. ...
Posted by Michael Wonder on 09 Dec 2021
Nivolumab for the adjuvant treatment of oesophageal carcinoma: indication of minor added benefit
1 December 2021 - Those affected develop fewer relapses than if they wait and see. ...
Posted by Michael Wonder on 05 Oct 2021
Nivolumab and ipilimumab: added benefit in pleural mesothelioma with non-epithelioid tumour histology
1 October 2021 - For the first time, a pure antibody combination has been approved as a first-line therapy for ...
Posted by Michael Wonder on 05 Oct 2021
Adjuvant treatment for NSCLC: osimertinib mesylate may benefit certain people
1 October 2021 - Hint of considerable additional benefit if, after complete tumour resection, adjuvant platinum-based chemotherapy has already been ...
Posted by Michael Wonder on 16 Sep 2021
Nivolumab in skin cancer: additional benefit upgraded on the basis of an indirect comparison
16 September 2021 - For nivolumab (Opdivo), the pharmaceutical company was able to achieve a significantly better result in a second ...
Posted by Michael Wonder on 15 Sep 2021
Venetoclax in acute myeloid leukaemia: indication of a considerable added benefit
15 September 2021 - Third new area of application/those affected still live a good year on average - and thus ...
Posted by Michael Wonder on 09 Aug 2021
Quality assurance requirements of the G-BA also apply to new CAR-T cell therapy
5 August 2021 - The Federal Joint Committee (G-BA) today evaluated the new cancer drug with the trade name Tecartus and ...
Posted by Michael Wonder on 22 Apr 2021
Novartis to discontinue sales of Piqray in Germany
21 April 2021 - The sale of Piqray (alpelisib) will be discontinued by Novartis in accordance with Section 4 (7) ...
Posted by Michael Wonder on 04 Jan 2021
Ibrutinib with rituximab in previously untreated chronic lymphocytic leukaemia: indication of added benefit over FCR
4 January 2020 - The new drug combination prolongs overall survival in patients in good general health. No study data are ...
Posted by Michael Wonder on 17 Sep 2020
The best possible security of supply for cancer therapy with CAR-T cells
17 September 2020 - Medical facilities that treat patients with novel cell therapies (CAR-T cells) must meet newly defined quality requirements. ...